Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating treatments for HER2-positive advanced breast cancer in patients who have already received at least two prior anti-HER2 therapies. This Phase III clinical trial compares the effects and safety of TQB2930, a HER2 bispecific antibody drug, combined with chemotherapy, against trastuzumab combined with chemotherapy. The study aims to evaluate which treatment approach may better manage advanced breast cancer that has progressed despite prior therapies. Participants are randomly assigned to one of two groups. One group receives TQB2930 injection at 30 mgkg every three weeks along with a chemotherapy agent chosen by the investigator, with each treatment cycle lasting 21 days. The other group receives trastuzumab starting with an 8 mgkg dose followed by 6 mgkg every three weeks, combined with investigator-selected chemotherapy, also given in 21-day cycles. Chemotherapy options include drugs like Capecitabine, Gemcitabine, Vinorelbine, or Eribulin. Throughout the study, participants undergo regular assessments to monitor disease progression and treatment response, including scans and evaluations lasting about one to two years. The main outcome measured is progression-free survival as assessed by an independent review committee. Additional outcomes include overall survival, duration of response, tumor response rates, and safety monitoring for adverse events. Blood samples are collected at specific cycles to measure drug levels and immune responses. The study includes safety follow-up for 90 days after the last dose or until another anticancer treatment begins.
Actively Recruiting
Researchers are evaluating early minimally invasive surgery with thrombolysis eMIST compared to the best medical management in patients with acute spontaneous supratentorial intracerebral hemorrhage ICH of 20 mL or more. This multicenter, randomized, adaptive clinical trial aims to improve functional outcomes after stroke caused by this type of brain hemorrhage. The trial uses a prospective, open-label design with blinded assessment of results and includes adaptive sample size estimation based on interim follow-up data. Participants are randomly assigned to receive either early minimally invasive catheter evacuation followed by up to ten doses of urokinase to dissolve the clot, or the best available standard medical care without surgery. The urokinase doses are administered through a catheter placed directly into the hemorrhage site, aiming for clot resolution. The randomized intervention must start within specific timing windows after stroke onset to be included. During the study, participants undergo assessments including head CT scans, functional evaluations using the utility-weighted modified Rankin Scale at multiple time points up to 180 days, and other measures such as quality of life and daily living activities. Safety and efficacy are monitored throughout the trial, which lasts until study completion in 2028. Researchers focus on functional improvement as the primary outcome, with additional secondary measurements including mortality and clot removal at defined times.